Vaccination for Human Papillomavirus Infection Treatment

Main Article Content

นราพร สมบูรณ์นะ ภูริวัจน์ สุขวัฒนนิพัทธ์ สิริกานต์ จันทร์ประอบ

Abstract

Human papillomavirus (HPV) can cause cervical cancer,the second most common cancer among Thai womenfollowing breast cancer. HPV can alsocause other clinical diseases, such as genital warts in both male and female. HenceHPV treatment and protectionarenecessary. To date,several DNA vaccines have been developed as therapy, becausethe DNA vaccine is stable, and its target and effectiveness are high using nanoparticle-assisted delivery, e.g. chitosan nanoparticles. This review article will present details on biology of HPV, current treatments for HPV infection and DNA vaccine. Together, the knowledges will promote understanding and further scientific development about effective HPV vaccine.

Keywords

Article Details

Section
Review Article

References

1. สถาบันมะเร็งแห่งชาติ กรมการแพทย์ กระทรวงสาธารณสุข.ทะเบียนมะเร็งระดับ โรงพยาบาล พ.ศ. 2559 [ออนไลน์]. 2018 [เข้าถึงเมื่อ 25 พฤษภาคม 2561]. เข้าถึงได้จาก Available from: http://www.nci.go.th/th/File_download/Nci%20Cancer%20Registry/Hospital-Based%20NCI2%202016%20Web.pdf

2. Bernard H, Burk R, Chen Z, Doorslaer K, Hausen H, Villiers E.Classification of Papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401(1):70-9.

3. Stanley MA.Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 2012;93:681-91.

4. Conway M, Meyers C. Replication and assembly of Human papillomaviruses. J Dent Res 2009;88(4): 307-17.

5. Hung C, Ma B, Monie A, Tsen S, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.Expert Opin Biol Ther 2008;8(4):421-39.

6. Li L, Herndon J, Truscott S, Hansen T, Fleming T, Goedegebuure P, et al. Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine 2010;28:1911-8.

7. Pang CL, Thierry F.Human papillomavirus proteins as prospective therapeutic targets. Microb Pathog 2013;58:55-65.

8. Srisomboon J, Suprasert P.Cervicalcancer: prevention and treatment.Chiang Mai: Jarusbusinessprinting; 2008.

9. Pinto LA, Dillner J, Beddows S, Unger ER. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 2018;36(32 Pt A):4792-9.

10. Hutchinson DJ, Klein KC. Human papillomavirusdisease and vaccines. Am J Health Syst Pharm 2008;65(22):2105-12.

11. Juntasopeepun P, Suwan N, Phianmongkhol Y, Srisomboon J. Knowledge and Risk Behaviors of HPV Infection and Cervical Cancer among Female College Students: Implications for Sex Education and Health Care Policy. Thai J Nurs Council 2011;26(3):48-63.

12. Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol 2018;47:59-72.

13. Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 2018;5:46-58.

14. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012;11(2):189-209.

15. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, atherapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebocontrolled phase 2b trial. Lancet 2015;386(10008):2078-88.

16. ปิยวัฒน์ เลาวหุตานนท์. สถาบันมะเร็งแห่งชาติ. Cervical cancer [ออนไลน์]. [เข้าถึงเมื่อ 28 พฤษภาคม 2561]. เข้าถึงได้จาก Available from: URL: http://www.nci.go.th/th/File_download/thanong/01/มะเร็งปากมดลูก.pdf